Blue test tubes arranged in a line, disappearing into the background

Drug news

NICE recommends Forxiga (BMS/AstraZeneca) for combination in Type 2 Diabetes

Read time: 1 mins

Last updated:27th Jun 2013

Published:27th Jun 2013

Source: Pharmawand

NICE. the National Institute of Health and Care Excellence has varied its earlier recommendation made in February and now recommends the use of the the SGLT 2 inhibitor Forxiga (dapagliflozin) from BMS and AstraZeneca as a dual therapy in combination with metformin (if it is used as described for DPP4-inhibitors) or in combination with insulin.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Brain Stimulation publishes key RECOVER study data

The RECOVER clinical study published in Brain Stimulation shows that LivaNova's VNS Therapy system significantly improves depressive symptoms and quality of life in patients with treatment-resistant unipolar depression

6 mins

Drug news

FDA grants Breakthrough status to Trodelvy for SCLC

The FDA has granted Breakthrough Therapy Designation to Gilead's Trodelvy for second-line treatment of extensive-stage small cell lung cancer, based on promising results from the Phase 2 TROPiCS-03 study

1 min

Drug news

Ibrance combo boosts PFS survival by 15+ months in MBC

The Phase 3 PATINA study shows that Ibrance, combined with standard therapies, extends progression-free survival by over 15 months in HR+/HER2+ metastatic breast cancer

2 min

See all news